Stand-alone blood clot treatment works as well as standard therapy

07/22/2013 |

A clinical trial found a 2.3% incidence of venous thromboembolism in a group of patients taking the drug apixaban, compared with 2.7% in the group receiving enoxaparin and warfarin. Major bleeding occurred in 9.7% of patients in the standard treatment group and 4.3% of patients in the apixaban group. The study in the New England Journal of Medicine concluded that apixaban was as safe and effective as standard therapy in treating blood clots.

View Full Article in:

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Fort Worth, TX
Director, Senior Legal Counsel
Fort Worth, TX